
Week of December 12 – CAC2 Childhood Cancer Community News Digest
CAC2’s weekly update for news and community highlights.
CAC2’s weekly update for news and community highlights.
[vc_row][vc_column][vc_column_text]By CAC2 Member Jess Kean, Children’s Cancer Cause. The Comprehensive Cancer Survivorship Act was introduced in Congress on December 14, 2022. As the only childhood
[vc_row][vc_column][vc_column_text] Assorted News from the Last Week: For many patients, one of the most antagonizing parts of a hospital visit is paying for parking. Those parking
By Guest Blogger Sarah Milberg, Co-Chair of the Alliance for Childhood Cancer and Director of Government Relations and Advocacy for the St. Baldrick’s Foundation Thanks to
[vc_row][vc_column][vc_column_text] Assorted News from the Last Week: “I’d like to introduce you to Josh. . . Josh, a sound engineer, is also a childhood cancer
[vc_row][vc_column][vc_column_text] Assorted News from the Last Week: CAC2 Member Mary Beth Collins explains the importance of the new FDA approval of Pedmark: “With the FDA’s
[vc_row][vc_column][vc_column_text] Assorted News from the Last Week: CAC2 Member Joe Baber reflects on the Gabriella Miller Kids First 2.0 legislation pending in Congress: “We’re all
By CAC2 Individual Member Joe Baber Because of my grandson, Conor, a neuroblastoma survivor, I have met so many people in our childhood cancer community
[vc_row][vc_column][vc_column_text] This month, Dr. Gregory Reaman was named by the Childhood Cancer Data Initiative (CCDI) as the new Scientific Director. In this role, Dr. Reaman
[vc_row][vc_column][vc_column_text] Assorted News from the Last Week: The FDA has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (AVE-PC) in